Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020
Transcript: Click here
Infographic: Click here
Biogen tops market estimates in Q3, lowers guidance. Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated.
Joe Mara — Head of Investor Relations
Michel Vounatsos — Chief Executive Officer
Alfred W. Sandrock, Jr. — Executive Vice President Research & Development
Michael McDonnell — Executive Vice President Chief Financial Officer
Terence Flynn — Goldman Sachs — Analyst
Marc Goodman — SVB Leerink — Analyst
Matthew Harrison — Morgan Stanley — Analyst
Umer Raffat — Evercore ISI — Analyst
Evan Seigerman — Credit Suisse — Analyst
Phil Nadeau — Cowen & Company — Analyst
Michael Yee — Jefferies — Analyst
Cory Kasimov — JPMorgan — Analyst
Ronny Gal — Bernstein — Analyst
Geoff Meacham — Bank of America — Analyst
Sumant Kulkarni — Canaccord — Analyst
Jay Olson — Oppenheimer — Analyst
Brian Abrahams — RBC Capital Markets — Analyst
